Parexel lays off US workers in restructuring

Contract drug researcher Parexel will spend up to $35 million to restructure, laying off or relocating 150 workers. COO Carl Spalding will retire at the end of June. Parexel officials says the restructuring was triggered by a change in the "geographic mix" of the business. The company is downsizing in the US as it expands and adds new workers abroad. Parexel expects to have a net increase in employment by the end of this quarter.

- read this article from the AP for more on the restructuring

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.